A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

NCT02373072 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson Disease

Interventions

DRUG: PF-06649751
DRUG: Trimethobenzamide Hydrochloride
DRUG: Placebo

Sponsor

Pfizer